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METHODS:
For the period October 2007 through July 2012, we reviewed lot validation data for each new lot of insulin-like growth factor 1 (IGF-1) reagents (Siemens Healthcare Diagnostics) at Mayo Clinic, Rochester, MN, and the University of Virginia, Charlottesville, VA. Analyses of discarded patient samples were used for comparison of lots. For the same period, we determined the distributions of reported patient results for each lot of reagents at the 2 institutions.
RESULTS: Lot-to-lot validation studies identified no reagent lot as significantly different from the preceding lot. By contrast, significant lot-to-lot changes were seen in the means and medians of 105 668 reported patient IGF-I results during the period. The frequency of increased results increased nearly 2-fold to a high of 17%, without detectable changes in the underlying patient demographics. Retrospective statistical analysis indicated that lot-to-lot comparison protocols were underpowered and that validation studies for this assay required testing Ͼ100 samples to achieve 90% power to detect reagent lots that would significantly alter the distributions of patient results.
CONCLUSIONS:
The number of test samples required for adequate lot-to-lot validation protocols is high and may be prohibitively large, especially for low-volume or complex assays. Monitoring of the distributions of patient results has the potential to detect lot-to-lot inconsistencies relatively quickly. We recommend that manufacturers implement remote monitoring of patient results from analyzers in multiple institutions to allow rapid identification of between-lot result inconsistency.
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Maintenance of long-term stability of analytical processes and results is a pivotal task for the clinical laboratory. This process typically includes a comparison of current and new reagent lots through paired measurements of patient samples, with predefined acceptance and rejection criteria (1 ) . Power calculations suggest that, for most assays, this approach should detect a shift in slope or intercept of 10% with 90% likelihood, if 20 -30 samples are tested, provided the analytical range is not too narrow (2, 3 ) . Each such assessment should also be compared to previous lot-to-lot evaluations to detect long-term trends. Finally, a comparison of QC values before and after a lot change, as well as external quality assurance data, might provide further data on equivalency, once the new lot has been in use for some time.
Despite these measures, clinically significant differences between lots may be missed. With some assays and some types of reagent changes, the statistical power of a standard lot-to-lot comparison can be reduced. When lot validation fails to detect a change, the first indications to the laboratory that something might be amiss are inquiries from clinicians about patient results that are at variance with the clinical picture. It can be daunting to confirm that this is due to assay problems, rather than idiosyncrasies of specific patient samples, a change in composition of the patient population, or pure chance.
During the last 2-3 years, our 2 laboratories were contacted with increasing frequency about reported serum concentrations of insulin-like growth factor 1 (IGF-1) 4 that appeared to be spuriously high. IGF-1 is measured to diagnose over-and underproduction of growth hormone and monitor growth hormone therapy (4 -6 ) . In many cases, experienced clinicians reported that the increased IGF-I concentrations were not associated with signs or symptoms of growth hormone excess.
Because lot-to-lot comparisons had been unremarkable during this period, we undertook to review whether other measures might have detected lot-to-lot inconsistencies. To this end, a) we determined whether long-term trends had occurred in the distributions of patient results for IGF-I as measured with the same assay method at 2 institutions, and b) we reexamined, with actual data and in theory, the actual and predicted performance of various methods that could be used to detect such trends in assay performance due to reagent lot-to-lot changes.
Materials and Methods
We examined results from reagent lot-to-lot comparisons that were performed between October 2007 and July 2012 at Mayo Clinic in Rochester, MN (total of 32 lots) and at the University of Virginia in Charlottesville, VA (UVa) (16 lots Patient result analysis included all IGF-1 results on patients age 21 years and older that were reported during the same time interval in the 2 institutions, plus samples from patients younger than 21 from UVa, to increase the smaller number of samples available for analysis there. The proportion of samples from patients younger than 21 at UVa showed no significant change between the first and last reagent lots tested (2-tailed P ϭ 0.67, Fisher exact test). Because most of the samples that were tested at the Mayo Clinic laboratory were outside referral samples, the only clinical and demographic information available for all of these patients was age and sex.
These studies were deemed exempt by the Mayo Clinic Institutional Review Board. The work at UVa was a search of deidentified data from the established data repository at this institution; such research is deemed exempt by the institutional review board.
IGF-1 ASSAY
We measured IGF-1 using the Siemens Immulite 2000 IGF-1 assay (Siemens Healthcare Diagnostics). The IGF-1 assay is a 2-site, solid-phase, enzyme chemiluminometric assay standardized against the National Institute for Biological Standards and Control (NIBSC) 1st International Reference Reagent 87/518. Because of freeze-thaw instability of IGF-1 in patient samples, 2 manufacturer-provided controls (IGF-1 in a protein/ buffer matrix) are used for monitoring day-to-day assay variability. With the use of these controls, the interassay imprecision is 5.5% CV at 58 ng/mL and 5.1% at 188 ng/mL. Reference intervals, on the basis of Elmlinger et al. (7 ), were verified and deemed acceptable at the time of test implementation at both institutions. We used these reference intervals throughout the study.
LOT-TO-LOT EVALUATIONS
At Mayo Clinic, we evaluated each new IGF-1 reagent lot by simultaneously testing 20 deidentified discard patient samples with the current lot and the proposed new lot. We selected samples to cover as much of the analytical measuring range of the assay (25-1600 ng/ mL) as possible. Continuous and complete data for lotto-lot performance comparisons of IGF-1 reagents were available from October 2007 through July 2012. We performed lot-to-lot comparison with Passing-Bablok regression analysis for estimation of the slope and intercept. Additional parameters evaluated were R 2 , difference between paired samples, and mean percentage difference between the results obtained with the 2 reagent lots. The acceptance criteria were slope between 0.90 and 1.10, intercept Ͻ12.5 ng/mL (Ͻ50% of lowest reportable value), R 2 Ͼ 0.95, and Ͻ10% mean difference between reagent lots. At UVa, the numbers of samples available for lot validations were insufficient for meaningful use of regression analysis; results were compared with fixed limits of acceptability for absolute differences.
CALCULATION OF MEAN AND MEDIAN IGF-1 CONCENTRATIONS
The mean numbers of patient samples tested with each reagent lot after introduction into use were 3192 (range 868 -7067) for the Mayo Clinic and 286 (range 73-497) for UVa. We calculated overall mean and median IGF-1 concentrations in these patient samples for each reagent lot. A total of 101 095 (Mayo Clinic) and 4573 (UVa) data points were included in the analysis.
FREQUENCY OF IGF-1 RESULTS OUTSIDE OF THE REFERENCE

INTERVALS
We tabulated the numbers of results below and above the reference interval for each age group and calculated percentages above and below. We plotted the results per lot number as percentage above and below the reference interval and as fold change from the first reagent lot included in the analysis (manufacturer's lot 401), which we used as baseline for comparison with subsequent reagent lots and calculation of the fold change in the number of results above or below the reference intervals.
DATA ANALYSIS
We performed 1-way ANOVA with Tukey-Kramer post hoc analysis on log-transformed IGF-1 data to identify significant differences in the log-transformed means of the various reagent lots.
We assessed the change between lot 1 and lot 32 using the Kruskal-Wallis test for nonparametric data. The distributions of the IGF-1 data from lots 1 and 32 were binned into results above, within, and below the reference limit and analyzed with the Kruskal-Wallis test for ordinal data. We used quantile regression to assess the impact of lot number and age group on median IGF-1.
Power calculations were performed with G-Power (8 ) and nQuery 6.0. As Passing-Bablok regression was used, sample sizes estimated for linear regression had to be doubled for this nonparametric regression method (2 ) .
In view of the close association of serum IGF-1 concentrations with age, we compared the age distributions of tested patients with the Kruskal-Wallis test for ordinal data (Mayo Clinic) or analysis of contingency tables by use of 2 and Fisher exact tests (InStat GraphPad software) (UVa) to determine whether age/ demographic shifts in the tested population might have influenced changes in IGF-1 results over time.
Results
FREQUENCY OF RESULTS OUTSIDE OF THE REFERENCE INTERVAL OVER TIME
The frequency of IGF-1 results above the upper reference interval cutoff nearly doubled over time at Mayo Clinic, from 8%-10% to 13%-17%, with a corresponding, but lesser, drop in the proportion of results below the lower reference interval cutoff (Fig. 1 , A and C; Table 1 ). The overall increase in rates of increased results was interrupted in May and June 2009 (lots 12, 13, and 14; corresponding manufacturer's lots 424, 425, and 428) by a temporary, but dramatic, drop in the frequency of increased results. The cause of this temporary decrease was later identified by the reagent supplier (9 ) . Similar, though less dramatic, changes in the frequency of results above and below the reference interval cutoffs were also observed at UVa (Fig. 1, B and D) . For the respective observation periods, no significant differences in the age distributions of patients were found in either institution.
RETROSPECTIVE ANALYSIS OF LOT-VALIDATION STUDIES
During this study, 32 different reagent lots were used at Mayo Clinic and 16 at UVa, 7 of which were common to both institutions. Evaluation of the regression slopes from the lot-to-lot comparisons of results for discard samples did not show a positive bias or long-term trend during the observation period at either institution. At Mayo Clinic, the Passing-Bablok slope of individual lot-to-lot comparisons fluctuated between 0.9 and 1.10 ( Fig. 2) , and all the lots used were considered acceptable on the basis of the predetermined criteria. Controls were also tested as part of the lot-to-lot verification process. In all instances, control results were within 2 SDs of the laboratory-established target mean.
Retrospective reevaluation of the power calculations on the basis of the historical performance of the IGF-1 assay indicated that it would have been necessary to test a minimum of 50 samples across the analytical range to achieve a 90% power to detect a shift in slope of Ͼ10% or intercept of Ͼ12.5 ng/mL, assuming a Passing-Bablok regression with a 0.05 level of significance. The power to detect such a shift in the slope or intercept with the approach that was actually used (testing 20 samples) was 50%.
CHANGES OF REPORTED IGF-1 CONCENTRATIONS WITH
CHANGES OF LOTS
Evaluation of the mean and median IGF-1 values of all patient results showed significant changes in both parameters over time, as well as significant fluctuations from lot to lot (Fig. 3) . Quantile regression analysis by patient age indicated that the changes were highly significant (P Ͻ 0.0001) in all age groups. Comparison of lot 1 and lot 32 also showed a significant increase (P Ͻ 0.0001) in IGF-1 median value (Table 1) and an 8% increase in the number of results above the reference interval. There were no significant changes in the age distribution of the tested patients (P ϭ 0.0854). By contrast, comparison of lot 1 to the lot with the lowest mean (lot 13), showed a 21.3% increase (2.0-fold increase) in the number of results below the reference interval (data not shown). We also observed fluctuations in the means of the controls; however, these did not parallel the changes in mean and median of the patient results.
Finally, comparison of the log-transformed IGF-1 reported patient results demonstrated multiple statistically significant changes of the transformed mean IGF-1 between reagent lots over time (see Supplemental Fig. 1 , which accompanies the online version of this article at http://www.clinchem.org/content/vol59/ issue8). At Mayo Clinic, there were 11 lot changes in which the log-transformed mean IGF-1 of all reported results differed significantly between 2 consecutive lots, Detecting Reagent Lot-to-Lot Changes despite that the respective lot-to-lot comparisons with 20 patient samples had been acceptable. In addition, this analysis shows that starting in March 2010 with lot 20, there has been a stabilization of the mean IGF-1 values between lots at significantly higher logtransformed means than with earlier lots. This corresponds to the increase in the frequency of increased results, which had started in early to mid-2010 (Fig. 1) . For UVa, with much smaller numbers of reported patient results for each lot, comparison of the means by the (multiple comparison correcting) Tukey-Kramer test demonstrated no significant changes.
Discussion
This study shows that there was an increase in the proportion IGF-1 results above the upper reference limit at both institutions over time, despite acceptable results of lot-to-lot comparison studies. No significant upward trends in the slopes of the regression fits for the individual lot-to-lot comparisons were observed over the nearly 5-year monitoring period. The increase in rate of abnormally increased results corresponded to a stepwise rise in the patient population means and medians, which could not be explained by changes in patient age demographics. While this paper was in preparation, the assay's manufacturer independently reported an increase in the proportion of results above the reference range, which they had detected through analysis of anonymized patient results obtained by real-time monitoring of Immulite 2000 instruments in clinical laboratories (9 ) . Our findings highlight the challenges of current processes to maintain lot-tolot consistency by clinical laboratories and also raise the question of whether the manufacturer's release criteria are stringent enough. Unfortunately, it is often the laboratories that alert manufacturers to problems with reagent lots that have been released to the market.
Lot-to-lot variability is one of the main contributors to analytical variation in immunoassays (10 -13 ) . Lot-to-lot consistency is particularly critical when an analyte is used for monitoring, or when small changes in concentration might trigger further laboratory testing, imaging, invasive tests, or therapeutic interventions. Because of the importance of lot-to-lot consistency, laboratory regulations and accreditation standards require that each new reagent lot be evaluated before use. Unfortunately, currently neither universally accepted guidelines on how to perform such evaluations nor consensus as to the criteria for acceptability exist.
Whereas many laboratory scientists, as well as the College of American Pathologists, believe that patient samples should be included in lot-to-lot comparisons (14 ) , this can be difficult to do for assays with low testing volumes. Apart from the costs, smaller laboratories may not have enough residual patient samples to adequately cover the analytical range. Consequently, the lot-to-lot evaluation of an esoteric assay such as IGF-1 might include only a limited number of patient samples that often do not cover the analytical range. For IGF-1, this represents an especially serious problem for 2 reasons: (a) the analyte must be dissociated from IGF-binding proteins, which vary from sample to sample; and (b) the IGF-1 analytical range is broad and normal reference intervals differ with age, again making it difficult to achieve adequate coverage with representative patient samples. Our experience emphasizes that even the use of a modestly large pool of well-selected patient samples does not guarantee that significant lot-to-lot changes will be detected. Using 20 patient samples for every lot-to-lot comparison at the Mayo Clinic, we failed to detect 11 lot-to-lot changes (in a total of 32 lot-to-lot comparisons) that were retrospectively identified to have produced significant changes in mean patient results. On the basis of a retrospective analysis of lot-tolot performance and assay variability, our statistical analysis indicated a power of only 50% to detect the above changes for each lot-to-lot comparison. However, if this 50% probability for detection is correct, it is extremely unlikely that all 11 lot-to-lot comparisons found to produce different patient results would have gone undetected. Clearly, additional factors must be in play. One possibility is that the criteria might be too loose. For an assay with a large overall gaussian range of results, and a population result SD of almost one-third of the overall population mean, as for IGF-1, a 10% upward bias can be expected to roughly double the number of results above the upper reference interval, a situation not too dissimilar to what we actually observed in our retrospective result frequency counts.
On the basis of these considerations, to detect a 10% bias, a larger number of patient samples (minimum of 50) needs to be tested in a lot-to-lot comparison for analytes such as IGF-1. As indicated above, even this may still not adequately address the issue, because the slope acceptance criteria might have to be tightened for this particular analyte, perhaps to 5%, which would likely require Ͼ100 patient samples for adequate power. The costs and logistics of such a large and repeated undertaking would likely be impossible to shoulder for all but large referral laboratories.
This study also highlights the importance of evaluating the cumulative effects of lot-to-lot variability in addition to the pairwise comparison when a new lot of reagent is introduced. Although we did not observe an obvious positive trend in the slope of the lot-to-lot comparisons, 6 of the 15 slopes from 2010 -2012 were "strongly positive" (Ͼ1.05), whereas none were "strongly negative" (Ͻ0.95). This correlates with the increased frequency of positive results that started in 2010. In cases where low-powered lot-to-lot verification procedures are performed, this cumulative difference will go undetected, allowing for a drift to occur 1 insignificant step at a time.
An alternative approach monitors assay stability by continuously plotting the distribution of patient results over the lifespan of the assay. Monitoring of patient results over time, on the basis of moving averages, has been used for many years for QC of hematology instruments (Bull algorithm) (15, 16 ) . This concept is not widely used for immunoassays. In this study, we demonstrate that medians and means of patient results could be used to detect trends and shifts in assay performance. Shifts in patient means or medians occurring in conjunction with reagent lot changes should trigger further investigation.
Use of the distribution of patient results for quality assurance must be done carefully to be meaningful. An underlying assumption of this approach is that the patient population is stable over time. Therefore, a possible change in the patient population should be considered when investigating a sudden change in mean or median values. The choice of mean vs median will depend on the result distribution (normal or not), width of the expected population result range, number of samples tested in the laboratory, and frequency at which the analysis is intended to be performed. The use of the median has the advantage of being more resistant to outliers, whereas parametric statistical analysis of changes in a gaussian mean may have higher statistical power given the same sample size. In 1 of the 2 laboratories in this study (Mayo Clinic), which has a testing volume of approximately 100 samples per day, analyses of the mean and median were closely concordant regarding statistically significant differences. However, The criterion of acceptability is a slope between 0.9 and 1.1. All lots presented here were deemed acceptable according to the slope criterion and the other in-house lot-to-lot acceptability criteria described in the main text. *Lots that were subsequently found to be significantly different from the preceding lot, on the basis of the retrospective analysis of log-transformed mean IGF-1 values of patient results that had been reported with that reagent lot.
in the other laboratory (UVa) with an average testing volume of 6 samples per day and 286 samples per lot number, comparison of the medians was not as sensitive as comparison of means for detecting statistically significant differences between lots. The ideal number of samples to include in the analysis will vary depending on the data distribution. It has been suggested that 200 patient results are sufficient for monitoring means or medians for data from approximately gaussian distributions (17 ) . However, data that are not normally distributed may require larger sample sizes (approximately 1000 results) (17 ) .
The manufacturer of the IGF-I reagent used the above approach-analysis of median trends of large numbers of results-to confirm in late 2012 that their IGF-1 assay had an increasing upward bias (9 ) . The data for this analysis was obtained through remote instrument downloads from consenting customer sites. Most manufacturers now routinely use tools to remotely connect to instruments at customer sites to monitor instrument functioning and troubleshoot assay problems. The systems typically also have the capability to obtain patient results without accessing protected health information. We propose that these remote access systems be used to create, or feed, a realtime centralized repository for continuous monitoring of population means and medians for various assays, with data linked to reagent lot numbers. If enough laboratories allow access to their assay data, such a system could flag questionable reagent lots within hours, or at the most a few days, after they enter use. Temporary remedial actions or adjustments to results could be initiated almost instantaneously, along with root-cause analysis, timely lot recalls or replacements, and longterm adjustments to tackle identified causes. This would benefit all laboratories, especially those with low testing volumes, who will not be able to benefit from in-house mean and median tracking. However, even larger laboratories would be greatly benefited, as would the manufacturers, at least in the long term, through ultimately reduced overall costs and improved quality.
Last, clinical laboratory testing is about providing results that allow optimal patient care. The high lot-tolot variability observed for IGF-1 over the last few years demonstrates the human and financial impact of delays in confirming and solving assay problems. Feedback provided by clinicians at Mayo Clinic, after retrospective chart review of patients who had undergone IGF-1 testing, showed that about 5% of all IGF-1 tests were false positives. Similarly, in an 8-month period in 2011, 1 of us at UVa (D.E. Bruns) was contacted about 20 abnormally high IGF-1 results in 17 patients that did not agree with clinical findings. In 17 of the 20 samples, the IGF-1 concentrations measured by a mass spectrometric method (18 ) were within reference intervals. In 7 of the patients, expensive growth hormone suppression tests were done; the results were within reference intervals in 6, with the result in the seventh nondiagnostic. If the Mean and median IGF-1 concentrations of patients' results were plotted for each lot number in the sequence that they were in use from October 2007 through July 2012. *Lot numbers that showed a significant change in the log-transformed IGF-1 mean compared to the previous lot. A, Mayo Clinic; B, UVa.
Mayo Clinic observations are generalized, a laboratory performing 1000 IGF-1 tests/month would be expected to generate around 50 false-positive results each month. Some of these can be expected to lead to follow-up appointments or further testing and, ultimately, increased financial burden and anxiety for patients.
In conclusion, on the basis of these findings and the statistical considerations outlined here, we propose that centralized monitoring of patient population means/medians and outlier rates in near real-time could flag questionable reagent lots almost immediately after they enter use. This would potentially avoid, or at least mitigate, the adverse clinical outcomes and increased healthcare costs that are typically associated with spurious abnormalities in laboratory results.
